Ocugen Expands Focus on Inherited Retinal Disorders by Licensing Novel Modifier Gene Therapy Platform

Ocugen, Inc. has obtained an exclusive worldwide license to develop and commercialize future ophthalmology products based on groundbreaking technology developed by Neena Haider, PhD, Associate Professor of Ophthalmology. Learn about this technology and read the full press release.